5-[1,1-Difluoro-2-[2-(trifluoromethyl)pyrimidin-4-yl]oxyethyl]-2-methylsulfanyl-4-piperidin-4-ylpyrimidine;hydrochloride

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 5-[1,1-Difluoro-2-[2-(trifluoromethyl)pyrimidin-4-yl]oxyethyl]-2-methylsulfanyl-4-piperidin-4-ylpyrimidine;hydrochloride
• 英文别名: 5-[1,1-difluoro-2-[2-(trifluoromethyl)pyrimidin-4-yl]oxyethyl]-2-methylsulfanyl-4-piperidin-4-ylpyrimidine;hydrochloride
• 化学式: C17H19ClF5N5OS
• 分子量: 471.9
• InChiKey: WSEMAOZLIAOGOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.07
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  98.1
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• [EN] RORY MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR GAMMA ORPHELIN ASSOCIÉ AUX RÉTINOÏDES (RORY)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014062938A1

  公开（公告）日：2014-04-24

  Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by "q", the ring system denoted by "A" and the ring system denoted by "B" are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

  描述了化学式(I)中的RORy调节剂，以及其N-氧化物、药用可接受的盐、溶剂和水合物，其中R1、R2、R3、R4、R5、R6、Ra、x、y、L、G、Z、由“q”表示的键，由“A”表示的环系统和由“B”表示的环系统在此处进行了定义。还提供了包含这些化合物的药物组合物。这些化合物和组合物在调节细胞中的RORy活性的方法和治疗患有需要从RORy活性调节中获益的疾病或紊乱的受试者的方法中是有用的，例如自身免疫和/或炎症性疾病。
• RORGamma Modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150266856A1

  公开（公告）日：2015-09-24

  Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R a , x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

  本文描述了公式（I）的RORy调节剂及其N-氧化物、药学上可接受的盐、溶剂和水合物，其中R1、R2、R3、R4、R5、R6、Ra、x、y、L、G、Z、“q”表示的键、表示的环系统“A”和表示的环系统“B”在此定义。还提供了包含这些化合物的制药组合物。这些化合物和组合物在调节细胞中的RORy活性的方法和治疗患有疾病或障碍的受试者中是有用的，其中该受试者在调节RORy活性方面具有治疗益处，例如自身免疫和/或炎症性疾病。
• RORγ modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10035790B2

  公开（公告）日：2018-07-31

  Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.

  描述了式 (I) 的 RORy 调节剂、其 N-氧化物、其药学上可接受的盐、其溶液和水合物，其中 R1、R2、R3、R4、R5、R6、Ra、x、y、L、G、Z、用 "q "表示的键、用 "A "表示的环系和用 "B "表示的环系在本文中定义。此外，还提供了包含这些化合物的药物组合物。此类化合物和组合物可用于调节细胞中 RORy 活性的方法和治疗患有疾病或失调的受试者的方法，其中受试者将从调节 RORy 活性中获得治疗上的益处，例如自身免疫和/或炎症性失调。